The metabolic syndrome (MetS) or insulin resistance syndrome is widespread and multi-factorial disorder. This article aims to assess and observe samples with the MetS to start efforts to take the proper treatments to minimize the risk of cardiovascular diseases. Additionally, we evaluate the association of Helicobacter pylori (H. Pylori) Ab tests with MetS. To meet this goal, 350 reviewers of K1 Hospital are participated in this work for six months from October 2016 to March 2017. The patients (N=350) are divided into two groups, a group subjects with MetS (N=109), whereas the latter is without MetS (N=241). A venous blood sample is taken after 8 hours of fasting to measure fasting blood glucose, H. Pylori Ab test, and other required biochemical assays. Additionally, blood pressure (BP), Body Mass Index (BMI) (i.e. weight and height), and waist circumference are measured. The assays revealed that the frequency of MetS is 31.1% as per the modified National Cholesterol Education Program Adult Treatment Panel III (NCEP: ATPIII) criteria. Furthermore, a statistically significant age (p=0.02) corresponded higher rate of MetS cases is larger than 40 years old (i.e. 69%). Moreover, BMI recorded as (27.6 ± 4.4 vs 31.4 ± 4.5, p <0.001), height (169 ± 8.4 vs 168.1 ± 8.5, p ≤ 0.11), weight (78.8 ± 12.3 vs 88.6 ± 13.2, p<0.01) and waist circumference (83.3 ± 16.1 vs 96.3 ± 11.6, p<0.001). Besides, BP showed positively correlation with systolic (120.3 ± 10.6 vs 130.6 ± 10.8, p<0.04) and diastolic (70.9 ± 0.9 vs 80.8 ± 10, p<0.01). The biochemical assays for employees with and without MetS are mean values of fasting serum glucose (5.3 ± 1.4 vs 7.5 ± 3.2, p ≤ 0.001). The highest average total cholesterol recorded as (4.3 ± 1.3 vs 4.9 ± 1.3, p ≤ 0.001), serum triglyceride (2 ± 1.5 vs 2.8 ± 1.2, p ≤ 0.001) and lower HDL levels (1.2 ± 0.5 vs 0.8 ± 0.1, p ≤ 0.001). Accordingly, the results showed that H. Pylori infection is associated significantly with metabolic syndrome. In consequence, the outcome demonstrated high rates of obesity and overweight in MetS cases.
Metabolic syndrome; Helicobacter pylori; H pylori; Ab Test; K1 Hospital
Recently, a large number of organizations have argued that the MetS be introduced into clinical practice as a multidimensional risk concern for both type?2 diabetes and atherosclerotic cardiovascular disease (ASCVD) . It is a severe issue that can lead to fatal consequences if not identified and treated. Nowadays, clinical laboratories (lab) are crucial in identifying MetS. The available technologies enable these labs to provide clinical trial sponsors and healthcare providers the accurate outcomes to aid treatments and prevention as well . Haller and Hanefeld  coined the term metabolic syndrome. MetS are defined as a combination of underlying risk that culminates in adverse results when occurring together. These include cardiovascular disease, type 2 diabetes mellitus  and in consequence six-fold increase in death rates . Developing MetS leads to main risks such as a diet high in carbohydrates and fats, and physical inactivity. Accordingly, two central clinical features are likely to occur which are insulin resistance and central obesity. Obesity is considered from the essential elements of MeTS which may precede the emergence of risk factors in MetS . MetS is a constellation of cardiovascular risk factors in one individual that anticipates about the two-fold increased risk of cardiovascular events and three-fold increased risk for new-onset type 2 diabetes.